Inari Medical (NARI) Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inari Medical in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NARI shares.
View NARI analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued twelve-month price objectives for Inari Medical's stock. Their NARI share price forecasts range from $65.00 to $100.00. On average, they expect the company's stock price to reach $85.25 in the next twelve months. This suggests a possible upside of 30.4% from the stock's current price.
View analysts price targets for NARI or view top-rated stocks among Wall Street analysts.

Inari Medical's stock was trading at $63.56 at the beginning of 2023. Since then, NARI stock has increased by 2.9% and is now trading at $65.40.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our NARI earnings forecast.

Inari Medical, Inc. (NASDAQ:NARI) issued its quarterly earnings data on Wednesday, August, 2nd. The company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.18. The business had revenue of $119.01 million for the quarter, compared to analysts' expectations of $116.67 million. Inari Medical had a negative net margin of 3.66% and a negative trailing twelve-month return on equity of 3.80%. The company's revenue for the quarter was up 28.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.19) EPS.

ETFs with the largest weight of Inari Medical (NASDAQ:NARI) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P MidCap 400 Pure Growth ETF (RFG), Principal Healthcare Innovators ETF (BTEC) and IQ Healthy Hearts ETF (HART).iShares U.S. Medical Devices ETF (IHI).

Inari Medical issued an update on its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $482.00 million-$492.00 million, compared to the consensus revenue estimate of $483.82 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inari Medical investors own include NVIDIA (NVDA), Home Depot (HD), CVS Health (CVS), QUALCOMM (QCOM), Thermo Fisher Scientific (TMO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Procter & Gamble (PG) and Bristol-Myers Squibb (BMY).

(NARI) raised $110 million in an initial public offering on Friday, May 22nd 2020. The company issued 7,300,000 shares at $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers.

Inari Medical trades on the NASDAQ under the ticker symbol "NARI."

Shares of NARI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NARI stock can currently be purchased for approximately $65.40.

Inari Medical (NASDAQ:NARI) has a market capitalization of $3.75 billion and generates $383.47 million in revenue each year. The company earns $-29,270,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

The company employs 1,100 workers across the globe.

Inari Medical's mailing address is 9 Parker Suite 100, Irvine CA, 92618. The official website for the company is www.inarimedical.com. The company can be reached via phone at 877-923-4747 or via email at ir@inarimedical.com.